In animal experiments, treatment with anti-CCR5 antibodies effectively reduced the infiltration of CCR5+CD8+ T lymphocytes in the liver, thereby alleviating liver damage caused by acute GVHD (115). Here, CD8A is linked to acute graft versus host disease.